Difference between revisions of "Ovarian cancer screening"

Jump to: navigation, search
Line 16: Line 16:
 
**[[Transvaginal ultrasound]] ([[TVU]])
 
**[[Transvaginal ultrasound]] ([[TVU]])
 
**Multimarker panels and bioinformatic analysis of proteomic patterns<ref name="pmid28170086">{{cite journal| author=Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D et al.| title=Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. | journal=CA Cancer J Clin | year= 2017 | volume= 67 | issue= 2 | pages= 100-121 | pmid=28170086 | doi=10.3322/caac.21392 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28170086  }} </ref>
 
**Multimarker panels and bioinformatic analysis of proteomic patterns<ref name="pmid28170086">{{cite journal| author=Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D et al.| title=Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. | journal=CA Cancer J Clin | year= 2017 | volume= 67 | issue= 2 | pages= 100-121 | pmid=28170086 | doi=10.3322/caac.21392 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28170086  }} </ref>
*The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)is evaluating a multimodal screening strategy (MMS) efficacy which consists of:
+
*The [[UK Collaborative Trial of Ovarian Cancer Screening]] ([[UKCTOCS]])is evaluating a multimodal [[screening]] [[strategy]] ([[MMS]]) [[efficacy]] which consists of:
**annual CA 125 screening, risk of ovarian cancer algorithm (ROCA), TVU <ref name="pmid28170086">{{cite journal| author=Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D et al.| title=Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. | journal=CA Cancer J Clin | year= 2017 | volume= 67 | issue= 2 | pages= 100-121 | pmid=28170086 | doi=10.3322/caac.21392 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28170086  }} </ref>
+
**Annual [[CA125]] screening, risk of [[ovarian cancer]] algorithm ([[ROCA]]), TVU <ref name="pmid28170086">{{cite journal| author=Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D et al.| title=Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. | journal=CA Cancer J Clin | year= 2017 | volume= 67 | issue= 2 | pages= 100-121 | pmid=28170086 | doi=10.3322/caac.21392 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28170086  }} </ref>
*Patients with family history of ovarian cancer or breast cancer can have ovarian cancer hereditary syndrome as breast-ovarian cancer syndrome which is associated with
+
*Patients with family history of [[ovarian cancer]] or [[breast cancer]] can have [[ovarian cancer hereditary syndrome]] as [[breast-ovarian cancer syndrome]] which is associated with
**BRCA1 and BRCA2 gene mutations
+
**[[BRCA1]] and [[BRCA2]] [[gene mutations]]
**Lynch II syndrome  
+
**[[Lynch II syndrome]]
*Should undergo the following screening:
+
*Should undergo the following [[screening]]:
**Annual rectovaginal pelvic examinations
+
**[[Annual]] [[rectovaginal]] [[pelvic examinations]]
**CA 125
+
**[[CA 125]]
**TVU untilcompleting childbearing or until age 35 years at least, where at this point prophylactic bilateral oophorectomy is recommended
+
**[[TVU]] until completing [[childbearing]] or until age 35 years at least, where at this point [[prophylactic]] [[bilateral]] [[oophorectomy]] is recommended<ref name="pmid28170086">{{cite journal| author=Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D et al.| title=Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. | journal=CA Cancer J Clin | year= 2017 | volume= 67 | issue= 2 | pages= 100-121 | pmid=28170086 | doi=10.3322/caac.21392 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28170086  }} </ref>
 
== References ==
 
== References ==
 
{{reflist|2}}
 
{{reflist|2}}

Revision as of 18:39, 12 July 2019


Ovarian cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classifications

Pathophysiology

Causes of Ovarian cancer

Differentiating Ovarian cancer from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Staging

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ovarian cancer screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ovarian cancer screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ovarian cancer screening

CDC on Ovarian cancer screening

Ovarian cancer screening in the news

Blogs on Ovarian cancer screening

Directions to Hospitals Treating Ovarian cancer

Risk calculators and risk factors for Ovarian cancer screening

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

References

  1. 1.0 1.1 Galea M, Gauci G, Calleja-Agius J, Schembri-Wismayer P (2017). "Peritoneal biomarkers in the early detection of ovarian cancer". Minerva Ginecol. 69 (1): 84–99. doi:10.23736/S0026-4784.16.03943-5. PMID 27284942.
  2. 2.0 2.1 2.2 2.3 Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D; et al. (2017). "Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening". CA Cancer J Clin. 67 (2): 100–121. doi:10.3322/caac.21392. PMID 28170086.

Linked-in.jpg